TAK-901|934541-31-8|-陌孚医药/Medlife

您当前的位置：

TAK-901

目录号: PL13936 纯度: ≥99%

CAS No. :934541-31-8

商品编号	规格	价格	会员价
PL13936-5mg	5mg	¥1446.00	请登录
PL13936-10mg	10mg	¥2571.00	请登录
PL13936-50mg	50mg	¥7232.00	请登录
PL13936-100mg	100mg	¥12054.00	请登录
PL13936-200mg	200mg	询价	询价
PL13936-500mg	500mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	TAK-901
中文别名	5-[3-(乙基磺酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-B]吲哚-7-甲酰胺;5-[3-(乙基磺酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-b]吲哚-7-羧酰胺;5-[3-(乙硫酰基)苯基]-3,8-二甲基-N-(1-甲基-4-哌啶基)-9H-吡啶并[2,3-B]吲哚-7-甲酰胺;TAK901 抑制剂
英文名称	TAK-901
英文别名	TAK901;TAK-901;5-(3-(Ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide;5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide;5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide;PACLITAXEL C;5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide (ACI);TAK 901
Cas No.	934541-31-8
分子式	C₂₈H₃₂N₄O₃S
分子量	504.64
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

TAK-901是多靶点的的极光激酶 (aurora)抑制剂，对极光激酶A和B的IC₅₀ 值分别为21 和15 nM。

生物活性

TAK-901 is a multi-targeted aurora inhibitor with IC 50 s of 21 and 15 nM for aurora A and B, respectively.

性状

Solid

IC50 & Target[1][2]

Aurora A 21 nM (IC50) Aurora B 15 nM (IC

体外研究(In Vitro)

TAK-901 exhibits time-dependent, tight-binding inhibition of Aurora B, but not Aurora A. Consistent with Aurora B inhibition, TAK-901 suppresses cellular histone H3 phosphorylation and induces polyploidy. In various human cancer cell lines, TAK-901inhibits cell proliferation with effective concentration values from 40 to 500 nM. Examination of a broad panel of kinases in biochemical assays reveals inhibition of multiple kinases. However, TAK-901 potently inhibits only a few kinases other than Aurora B in intact cells, including FLT3 and FGFR2. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

In rodent xenografts, TAK-901 exhibits potent activity against multiple human solid tumor types, and complete regression is observed in the ovarian cancer A2780 model. TAK-901 also displayed potent activity against several leukemia models. TAK-901 induces pharmacodynamic responses consistent with Aurora B inhibition and correlating with retention of TAK-901 in tumor tissue. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Farrell P, et al. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther. 2013 Apr;12(4):460-70.

溶解度数据	In Vitro: DMSO : 2 mg/mL (3.96 mM; Need ultrasonic and warming)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation